Stock of the Day for November 5, 2024

Royalty Pharma Stock Report

Royalty Pharma
RPRX 90-day performance NASDAQ:RPRX Royalty Pharma
Current Price
$26.64
-0.90 (-3.27%)
(As of 11/6/2024 ET)
30 Day Performance
-3.37%
  
  
90 Day Performance
1.87%
  
 
1 Year Performance
-3.30%
  
  
Market Capitalization
$15.81B
P/E Ratio
23.58
Dividend Yield
3.15%
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

RPRX Company Calendar

AUG. 8, 2024
Last Earnings
AUG. 16, 2024
Ex-Dividend for 9/13 Dividend
SEP. 13, 2024
Dividend Payable
NOV. 6, 2024
Today
NOV. 6, 2024
Next Earnings (Confirmed)
NOV. 15, 2024
Ex-Dividend for 12/10 Dividend
DEC. 10, 2024
Dividend Payable
DEC. 31, 2024
Fiscal Year End

Recent Royalty Pharma News

Royalty Pharma plc (RPRX) Q3 2024 Earnings Call Transcript
Royalty Pharma reports Q3 revenue $565M, consensus $696.1M
Royalty Pharma Reports Third Quarter 2024 Results
Royalty Pharma (NASDAQ:RPRX) Raised to "Buy" at StockNews.com
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by abrdn plc
This report was written on November 5, 2024 and updated on November 6, 2024. This report first appeared on MarketBeat.com.